上海交大赵大海接受央视专访：中国新冠疫苗大规模接种将在一个月内启动
上海交通大学国际与公共事务学院博士生导师、上海交通大学-耶鲁大学卫生政策联合研究中心执行主任赵大海，自新冠肺炎疫情暴发以来，对于新冠疫情暴发、防控以及卫生政策第45次接受中央电视台专访，也是第70次接受央视、上视专访。2020年12月19日，赵大海在中央电视台英语频道的《中国24小时》节目，就中国新冠疫苗接种的意义等话题进行了直播访谈。现将访谈内容翻译并摘录如下。
主持人：新冠疫苗将在多大程度上有助于降低新冠病毒在中国本土局部暴发和反复的风险？
赵大海：虽然今年3月中旬以来，中国大陆的新冠疫情已得到控制，但局部暴发和死灰复燃的风险仍然很大。实际上，在北京、上海等地，新冠疫情已出现过局部暴发。考虑到新冠疫苗的有效性非常高，我相信新冠疫苗接种将大大降低新冠病毒在中国本土传播和卷土重来的风险。由于中国大陆绝大多数地区没有新的确诊病例，老百姓可能很难觉察到新冠疫苗接种带来的效果。然而，当边境在未来逐步放开的时候，新冠疫苗接种的意义将被充分意识到。
主持人：我们了解到，中国接种疫苗的意愿相对高于其他国家。在中国，全民接种疫苗有多远？
赵大海：考虑到在短时间内，新冠疫苗的生产能力有限，而且中国加入COVAX还要承担向其他国家提供大量新冠疫苗的责任，新冠疫苗不可能在很短的时间内满足所有人的需求。第一批重点人群疫苗接种将在不到一个月内启动。由于中国目前有5种新冠疫苗正在进行三期临床试验，中国所有人的大规模疫苗接种应该会在2021年秋季。此外，由于重点人群已接种疫苗，新冠疫情传播和卷土重来的风险已大大降低，普通市民可以耐心等待。
供稿者：上海交通大学
日期：2020年12月24日
Dahai ZHAO’s Exclusive Interview with CGTN: Mass vaccination in China will be all set to start within a month
Dahai Zhao, a doctoral supervisor at the School of International and Public Affairs of Shanghai Jiao Tong University and Executive Director of Shanghai Jiao Tong University-Yale University Joint Research Center for Health Policy, has been interviewed by ShanghaiTV for the 45nd time (the 70nd time by CGTN / ShanghaiTV) since the COVID-19 pandemic. On December 19, 2020, Zhao commented on the significance of COVID-19 vaccination in China on “China 24” of CGTN.
Anchor: How much will this help lower the risks of local spread and domestic resurgence in China?
ZHAO: Although the pandemic in the Chinese mainland has been under control since the middle of March this year, the risks of local spread and domestic resurgence are still very high. Actually, a lot of places such as Beijing, Shanghai witnessed the resurgences of the COVID-19 local outbreak.
Anchor: Considering the efficacy of COVID-19 vaccines is very high, I believe the vaccine inoculation will dramatically lower the risks of local spread and domestic resurgence in China. In China, how far is it to vaccinate all the people?
ZHAO: Given the limited production capacity of the COVID-19 vaccine in a short period of time, and China's accession to COVAX entails the responsibility of providing large quantities of COVID-19 vaccine to other countries, the COVID-19 vaccine is unlikely to meet everyone's needs in a very short period of time. The first vaccinations for priority populations will begin in less than a month. With five COVID-19 vaccines currently in phase III clinical trials in China, mass vaccination of all Chinese people should take place by autumn 2021. In addition, the risk of COVID-19 transmission and resurgence has been greatly reduced as key populations have been vaccinated, and ordinary citizens can wait patiently.
Contributor: SJTU
Data: December 24, 2020